aware that there is also a pending motion in relation to this case and we will deal with the two matters collectively we don't believe we need an argument on the motion to dissolve the injunction tense well briefed and  good morning honest i'd like to start by focusing on the fundamental legal errors distinct from the fact errors in the district court's decision that we've asserted on appeal the first one is the court's motivation analysis which we believe ignored important plain limitations in a very general motivation analysis that does not deal with the specific claim limitations directed to solving the food and drug problem that the court found the panties here clearer fact two arguments that we have but i'd like to give a brief background to explain why the court's decision is hindsight driven and why these legal conclusions resulted in the wrong outcome here i don't think we need too much  used is it really primarily one of your arguments that nanotechnology wasn't developed enough to test to provide a reasonable expectation of success or to use really focusing more on a question of whether  the motivation has to be tied to every limitation we're focusing on the legal requirement that the motivations have to be tied to every limitation and if not if there is a role for inherently in this kind of analysis it requires that since you don't have the motivation the prior art inevitably take you to the to to the end and we think the courts have that there's two different questions as you said when you're not there with them motivation and then whether and then you're inherent the argument so i'm sticking with your motivation arguments for yes is your argument that nanotechnology wasn't fully developed you made that argument a little bit your blue brief but in the reply you focus more on the question of whether the motivation whether you could have an alternative motivation for purposes of having a motivation to combine correct and we think the fact that netta technology was not fully developed is a factor going into the motivation analysis the court never did the but nobody had labeled that of the problem until we came up with a better a better solution it's a year of your argument is simply have to stand because you identified another problem in addition to others that you said that all the problems had to be tied to the motivation of mine that the that the motivation to combine have to be tied to the claims it's not just that we discover the problem it's that we obvious just with a and b with the bases and we don't believe it would be obvious but that would be a very different obviousness argument because there are you know this drug obviously is not correct and using nanotechnology to make it smaller the prosecution history clearly supports that we added that to narrow it to only specify those formulations that resulted in the elimination of the food effect i'm very cautious about the apparent use of the word inherently there because we think the fundamental error that the court started with the claim she started with the claim and said does part of the claim render other parts of the claim inherent and then not only that she didn't apply the necessarily present standard she applied a if something with in there i think she she took the language from the same parts case farther than it will stretch and that if anything within this general motivation any of the millions of possible permutations she called it limitless enter summary judgment order for an unlimited array of possible combinations if anything in there is inherently a result in these properties i'm going to label those properties the parent because there are a property of the thing that has them that's completely circular reasoning and avoids  they tried to argue that you only get the claimed elimination of food in fact under very certain specific conditions you don't get it everywhere and we didn't we didn't dispute the fact that you only get in certain situations we set our specification gives you enough guidance to figure out where those are without undue experimentation but nobody at trial said if i do a b c d and e necessarily bad these food effect limitations in fact in some of the claims particularly the ones with the scent seven hundred context where you had a specific saying that specific things had a specific properties as soon as you start to have even in the in anticipation context as soon as you start have to have designed choices within the reference i could just pick a b c or d then a case of say well it's not a matter of probabilities it have to inevitably be there when you multiply that by obviousness you're combining two generalized subject matters with all the possible design choices all the possible different things that have reduced the food effect across all drug formulation no there's not there with it in a woman's marketing materials there were representative ideas about what this is what this is useful for they mention reduction in food effect a one had published data for three different drugs with respect to the facts and then upsizing two of them had a positive fact one of those two was an unknown drug the other one the district court specifically found was not a good contemporaneous with not dealing with nanotechnology but it goes into detail in explaining that food affects based on formulation changes are highly unpredictable and we think that kerik and other hypothetical i know the limitations see yes it does that render c not really a limitation anymore and just a description and therefore inherent if and i understand there's an at least from what i can tell there is no nothing even close to just combining a and will give you the food limitation see across the range i think if if they played by the side of a plane has three limitations and a force that inevitably always results obvious i think i think there's a problem with that formulation because the claim needs to be assessed as a whole in the first instance and so the obvious analysis with unexpected results and secondary considerations and everything need to face the claim as a whole that a lot of danger in breaking up the claim in the park and saying well this part would have been obvious but made in one of a lot of sort of obvious avenues and would you be really motivated to do that in view of unexpected results of  conclusion i think it's in page five eighty five of her document where she groups of patients and take the average outcome which is a negative point two and within that there's variation that's another part of graham's teaching was we had a lot of variation graham who's one of the top experts in the field looked at all these patients and i'm going to group them into two groups one has fast absorption they get a bad outcome the other one has dangerous option have a good outcome you explain it and i look continuation applications with respect to efforts to try to prosecute the claims without the c and those went up to the p tab and those were all those came back as obviously appealed them and of and the panel said those claims are obvious i think you can kind adjustable acetate with particle size of less than three hundred nanometers that's the prior art of less than three hundred in meters and there was evidence at the trial court that and the disappoint clearly found that she made a number of small dr beach called it a sweet spot that you get these very dramatic improvements in this weeks by that is that the prior art is there anything in the prior art that says that across an entire six three patent and the two hundred five patent went to the penalties for those attempts they were rejected and they responded to the patent office by telling them that the unexpected properties of the prior art patents were that you would get these improved through these improved properties including food effect happen to good effect references are sort of just never very specific they said greater violence than ability that doesn't necessarily mean food about well what it means is that if there is a food effect in the product and due to the particle size it will be solved it will be reduced we did not know it was because if you don't have a food effect to begin i think that's a little bit of their problem with respect to the unexpected result it was the district court we had a debate a clean construction debate about what was meant by no substantial difference and we were advocating that no substantial difference meant they were the same that there was no substantial difference like  art and so actually the sixty percent i think the people of the tribe and focusing on the sixty percent one is really the narrowest limitation in any of the planes regarding food effect sixty percent less so that the that's the the the one claim that claims in the more proof prove down to sixty percent so i think on the on the course construction on no substantial difference allows for a much higher food effect than sixty percent i don't focus of your obviousness and now no they were are they were the focus of our obvious not we did make the same arguments with respect and here and with respect to this claim limitation we said that the reduction in the food effect this broad reduction because it's the lowest to get sixty so saying that you're going to prove the food effect i think sixty percent is pretty much what you get and the evidence is that when you reduce the particle the only the only reason there's not a limitation there's not a lot of variations that are in the pan the only way the date they don't make it non obvious by saying we want to play not just three hundred but to top the two thousand so that's the that's where the argues are completely consistent and you can see did you provide expert testimony that saying that that the food effect and these our expert testimony said that the the problems of intercalation variability of food effect and of bioavailability are all there are a package deal you prove once you prove them all because that's all they're all caused by the particle well in the only case in here too was an argument i think that's what that's what the court observed it was it was in the end that a pretty similar fact here and we found that it was in here that well in that case the issue was when they reduced the are to get the claimed benefits and so here the prior art says use the smallest particle size that's the smallest particle size that anyone can make is the is the two to three hundred nanometers particle size they can make it smaller than that so they claim zero to two thousand but the prior art says use two hundred to three hundred which is the optimal particle size and it's the particle size that reduces the plane benefit they but the but the physical property of the particle size it sounds to me that you're arguing that that apart see isn't really a limitation at all no i think part c is as big in practicality it is all it is a limitation because but the problem with that is that they only enabled how you get that is party with particles less than three hundred nanometers you can't get that with particles greater than three hundred and i understand have been unable t are but for purposes of inherently it's a limitation and then it seems like it has to be a limit for it to be obvious it has to be a limitation that is present in the prior art in the to greet it says here and i'm still struggling with the notion that the evidence to save me from the district court asserting the efforts of a just talk about an improvement in bioavailability and doesn't come close  to no substantial difference in the scene well i think my eyes are two ways it's it's just up it's really it's just a result of measuring what you get when you follow the prior art when you fall apart the prior art if they had changed it's of claim limitation was part a was particle size less than three hundred m years ok then i would say yes you get that reduction cleaned every single time it's necessary you cannot get around it it's there it's part of it's of it's s and the application of heresy in the context in this way and then what do we do if you if you disagree well because because i think the court did in the court did two different things the court found factually that when you reduce particle size this small and you measure the result you get this as a factual matter and of the court where he didn't get you all this in another part of the problem for factual finding even if we agree with the factual findings she said you'll have some reduction in food of actually never she never tied the two together so do we send it back for more of the findings as it relates to inherent see or do we send it back for her to consider your enablement argument legal standard to the facts and see what she can see what you get and see what the result is in terms of factual finding as far as as far as if you reverse you also have to mean if if you do overruled or obviousness finding she didn't complete the analysis of on the handles that particular issue if she felt the law was different you have to handle that matter the way she saw it would be and there are other invalidity arguments that were raised at the court never addressed yes ok but i think a solution you get them in a liquid you get that's what you end up with and then the patents liversedge patent says that a person still in the r could easily deploy those into a dosage forms a person still never do that and then they set a person a skill in the art that easily determine owners in response to a part of the discussion that just occurred i do want to emphasize there was no testimony nor was there any finding that anything in particular every single time resulted in any of the food effect limitations  of that technology your friend reference the claim construction the construe courtesy did you address that yes i think it i think he had i think he just had it backwards he said that the claim construction was i think the word he used was better than the prior art the claim construction that we asserted and i don't remember the exact terminology that she adopted but it was basically commensurate with the inventive examples that we showed in the specification and prosecution history such that the product to be taken without regard to meal or there was something to that effect there was a clinical component to it but it was commensurate with what we disclose not better than the prior art was a big gap the prior art as we discovered had somewhere between a six hundred thirty and seven clearly a portion of your range fine definitions would be inherent and that you can't broaden their range and then argue that there's no inherently i think then he will first of all that opens up a whole of very different obviousness argument that they didn't make and that wasn't part of the trial because then you have more components that you have to combine in a certain specific way there the district court didn't find that there was a particular prior that that the prior art would have suggested a particular narrower range that you would have necessarily done when trying to solve this chaos of the problem or trying to solve an inner patient variability problem and she didn't she just didn't go down that path second we think that the the testimony at trial just inconsistent with the idea that particle size alone is everything i mean their  own expert and his cross examination testimony had a three one two eight three one two nine and you can see it in column thirty three of the patent is a lot of other work that have to go into this besides just make the particles a certain size you have to optimize  for the for the issues that the district court did not address i think the court i think i think that that goes back to the district court i think for the obviousness of the discussion that there is the complete absence of a record on inherently i think is sufficient for this court to rule in addition to the other grounds that we have asserted is particularly i think the graham argument and teaching way i think is is really compelling and that provides i think that in the